4//SEC Filing
LaFrence Andrew D.C. 4
Accession 0001493152-21-007807
CIK 0001349929other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 9:24 PM ET
Size
14.7 KB
Accession
0001493152-21-007807
Insider Transaction Report
Form 4
Vyant Bio, Inc.VYNT
LaFrence Andrew D.C.
Chief Financial Officer
Transactions
- Award
Stock option (right to buy)
2021-03-30+100,000→ 100,000 totalExercise: $4.61Exp: 2031-03-30→ Common stock (100,000 underlying) - Other
Common Stock, $0.0001 par value
2021-03-30+26,866→ 26,866 total(indirect: By Trust) - Other
Common Stock, $0.0001 par value
2021-03-30+29,336→ 29,336 total - Other
Stock option (right to buy)
2021-03-30+38,868→ 38,868 totalExercise: $1.56Exp: 2030-05-22→ Common stock (38,868 underlying) - Other
Stock option (right to buy)
2021-03-30+172,944→ 172,944 totalExercise: $1.56Exp: 2029-08-30→ Common stock (172,944 underlying)
Footnotes (4)
- [F1]Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
- [F2]Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 111,693 options are currently vested and 61,251 options to vest in equal monthly installments commencing April 30, 2021.
- [F3]Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 38,868 options vest upon the achievement of certain milestones.
- [F4]The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. Subject to continued employment, the option vests as to 25% of the shares on March 30, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on April 30, 2022.
Documents
Issuer
Vyant Bio, Inc.
CIK 0001349929
Entity typeother
Related Parties
1- filerCIK 0001850633
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 9:24 PM ET
- Size
- 14.7 KB